Emerging Applications of EpCAM-Targeted Nuclear Medicine Probes: Current Research and Future Perspectives

Area of Science:

• Nuclear medicine
• Molecular imaging
• Oncology

Background:

• Molecular imaging in nuclear medicine offers non-invasive tumor diagnosis and treatment through visualized functional localization.
• Development of radionuclide molecular probes is crucial for identifying specific tumor targets.
• Epithelial cell adhesion molecules (EpCAM) are promising tumor targets due to their prevalence and role in tumor progression.

Purpose of the Study:

• To provide a comprehensive review of recent advancements in EpCAM-targeted radionuclide probes.
• To focus on primary ligands such as DARPins, antibodies, and aptamers.
• To evaluate the benefits, challenges, and future directions of these probes.

Main Methods:

• Review of recent scientific literature on EpCAM-targeted radionuclide probes.
• Focus on DARPins (Designed Ankyrin Repeat Proteins), antibodies, and aptamers as targeting ligands.
• Evaluation of probe performance, including specificity, efficacy, and limitations.

Main Results:

• EpCAM is a widely present antigenic marker integral to tumor occurrence and progression.
• DARPins, antibodies, and aptamers show potential as ligands for EpCAM-targeted radionuclide probes.
• Each ligand type presents unique benefits and challenges regarding probe development and application.

Conclusions:

• EpCAM-targeted radionuclide probes represent a significant advancement in molecular imaging for cancer diagnosis and treatment.
• Further research is needed to optimize probe design and overcome existing challenges for clinical translation.
• The reviewed ligands offer diverse strategies for developing effective EpCAM-targeting agents.